Pulmonary mycotic infection is a lung disease caused by fungal infection, the most common mold is Aspergillus, including primary and secondary pulmonary Aspergillus infection. Primary is mold spores and other inhaled into the human lungs, secondary is other parts of the body mold through the lymph or blood to the lungs cause disease. Clinical manifestations commonly have fever, cough, sputum, hemoptysis, chest pain, chest tightness and dyspnea and other symptoms, its pathogenesis and the patient’s own immune system, in malnutrition, hypoproteinemia, and long-term use of broad-spectrum antibiotics, immunosuppressants or hormone therapy led to a decline in immunity, prone to lung mold infection. Therapeutic application of antifungal drugs, commonly used are fluconazole, itraconazole, voriconazole, caspofungin, etc. The course of anti-infective drugs is long, requiring 4-6 weeks or more, and the application of antifungal drugs while strengthening nutritional symptomatic support therapy.